Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBATE: Dorsocervical Brown Adipose Tissue Study
NCT06426082Not yet recruiting
- Sponsor
- Universidad de Almería
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of salbutamol in cardiometabolic disease (4 arms), sponsored by Universidad de Almería. Primary endpoint: Change in UCP1 expression in the dorsocervical area at 4 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
salbutamol
03
Conditions
cardiometabolic disease
Beyond the preview
Go deeper on NCT06426082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06426082.